Skip to main content
    R

    Regeneron Pharmaceuticals Inc (REGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $952.40
    -3.07 (-0.32%)

    Market Cap: $98.84B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Regeneron Pharmaceuticals Inc (REGN) Earnings: Report Dates and Results

    Updated Oct 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Regeneron Pharmaceuticals (REGN) is expected to report earnings on Jan 28, 2027. In the quarter ended Sep 30, 2026, Regeneron Pharmaceuticals reported EPS of $18.43, above the $13.76 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +14.84%
    Streak
    6 Q

    Upcoming Estimates

    Reports Jan 28, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$26.27
    Range$17.35 - $31.96
    25 analysts
    Revenue Consensus
    $5.97B
    Range$4.71B - $6.80B
    23 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$15.89
    Range$12.90 - $18.80
    9 analysts
    EPS Revisions
    7
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$13.12+21.1%
    60d ago$13.12+21.1%
    30d ago$12.73+24.8%
    7d ago$15.890.0%
    Current$15.89
    Revenue Consensus
    $4.60B
    Range$4.11B - $4.85B
    8 analysts

    Next Report

    REGN has an expected report date of Jan 28, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 129.6% above the $11.44 reported for the quarter ended Dec 31, 2025.

    REGN Earnings Call

    The latest REGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, REGN beat 35 and missed 5. Revenue for the quarter ended Sep 30, 2026 was $5.12B, up 36.5% from $3.75B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$18.43$13.76N/A+33.94%Beat+55.8%233 up, 2 downOct 30, 2026$5.12B
    Jun 30, 2026$12.53$8.00$7.64 - $12.33+56.63%Beat-2.8%220 up, 1 downJul 30, 2026$4.29B
    Mar 31, 2026$9.47$8.90$5.40 - $12.75+6.40%Beat+15.2%237 up, 8 downApr 29, 2026$3.61B
    Dec 31, 2025$11.44$10.75$8.38 - $13.78+6.42%Beat-5.2%195 up, 5 downJan 30, 2026$3.88B
    Sep 30, 2025$11.83$9.64$7.61 - $10.57+22.72%Beat-5.1%235 up, 9 downOct 28, 2025$3.75B
    Jun 30, 2025$12.89$8.44$4.25 - $9.45+52.73%Beat+11.5%215 up, 9 downAug 1, 2025$3.68B
    Mar 31, 2025$8.22$8.48$6.11 - $10.73-3.07%Miss-13.9%202 up, 12 downApr 29, 2025$3.03B
    Dec 31, 2024$12.07$11.19$8.77 - $13.51+7.86%Beat+1.8%216 up, 11 downFeb 4, 2025$3.79B
    Sep 30, 2024$12.46$11.70$10.14 - $13.56+6.50%Beat+7.5%224 up, 2 downOct 31, 2024$3.72B
    Jun 30, 2024$11.56$10.62$8.90 - $13.18+8.85%Beat+12.9%236 up, 0 downAug 1, 2024$3.55B
    Mar 31, 2024$9.55$10.10$8.56 - $11.62-5.45%Miss-5.4%225 up, 1 downMay 2, 2024$3.15B
    Dec 31, 2023$11.86$10.75$7.53 - $13.48+10.33%Beat-5.6%213 up, 4 downFeb 2, 2024$3.43B
    Sep 30, 2023$11.59$10.78$8.60 - $12.05+7.51%Beat+4.0%211 up, 1 downNov 2, 2023$3.36B
    Jun 30, 2023$10.24$9.90$7.83 - $10.84+3.43%Beat+4.8%203 up, 0 downAug 3, 2023$3.16B
    Mar 31, 2023$10.09$9.56$7.74 - $10.95+5.54%Beat-12.2%200 up, 2 downMay 4, 2023$3.16B
    Dec 31, 2022$12.56$10.01$5.12 - $12.69+25.47%Beat-47.0%210 up, 5 downFeb 3, 2023$3.41B
    Sep 30, 2022$11.14$9.48$2.83 - $11.66+17.51%Beat-27.5%212 up, 0 downNov 3, 2022$2.94B
    Jun 30, 2022$9.77$8.76$7.46 - $13.46+11.53%Beat-62.1%170 up, 4 downAug 3, 2022$2.86B
    Mar 31, 2022$11.49$9.80$8.37 - $11.23+17.24%Beat+16.2%144 up, 1 downMay 4, 2022$2.97B
    Dec 31, 2021$23.72$20.30$10.35 - $23.20+16.85%Beat+148.9%146 up, 2 downFeb 4, 2022$4.95B
    Sep 30, 2021$15.37$9.94$4.55 - $10.83+54.63%Beat+83.9%141 up, 0 downNov 4, 2021$3.45B
    Jun 30, 2021$25.80$17.71$6.63 - $24.55+45.68%Beat+260.3%18N/AAug 5, 2021$5.14B
    Mar 31, 2021$9.89$8.68$7.11 - $12.63+13.94%Beat+49.8%19N/AMay 6, 2021$2.53B
    Dec 31, 2020$9.53$8.29$5.35 - $11.13+14.96%Beat+27.1%21N/AFeb 5, 2021$2.42B
    Sep 30, 2020$8.36$6.99$5.06 - $10.43+19.60%Beat+25.3%17N/ANov 5, 2020$2.29B
    Jun 30, 2020$7.16$5.97$4.41 - $7.15+19.93%Beat+18.9%20N/AAug 5, 2020$1.95B
    Mar 31, 2020$6.60$6.09$4.78 - $7.38+8.37%Beat+48.3%19N/AMay 5, 2020$1.83B
    Dec 31, 2019$7.50$7.17$5.18 - $8.30+4.60%Beat+9.6%19N/AFeb 6, 2020$1.86B
    Sep 30, 2019$6.67$6.40$5.41 - $7.17+4.22%Beat+13.6%19N/ANov 5, 2019$1.74B
    Jun 30, 2019$6.02$5.42$4.99 - $5.65+11.07%Beat+10.5%17N/AAug 6, 2019$1.58B
    Mar 31, 2019$4.45$5.52$4.50 - $6.32-19.38%Miss-4.7%19N/AMay 7, 2019$1.37B
    Dec 31, 2018$6.84$5.60$4.60 - $6.57+22.14%Beat+30.8%20N/AFeb 6, 2019$362.60M
    Sep 30, 2018$5.87$5.06$4.44 - $6.04+16.01%Beat+47.1%21N/ANov 6, 2018$1.66B
    Jun 30, 2018$5.45$4.68$4.14 - $5.35+16.45%Beat+30.7%21N/AAug 2, 2018$1.61B
    Mar 31, 2018$4.67$4.34$3.58 - $6.59+7.60%Beat+59.9%22N/AMay 3, 2018$1.51B
    Dec 31, 2017$5.23$4.57$2.95 - $5.13+14.44%Beat+72.0%24N/AFeb 8, 2018$1.58B
    Sep 30, 2017$3.99$3.82$3.15 - $4.48+4.45%Beat+27.5%23N/ANov 8, 2017$1.50B
    Jun 30, 2017$4.17$3.18$2.82 - $3.50+31.13%Beat+47.9%21N/AAug 3, 2017$1.47B
    Mar 31, 2017$2.92$3.07N/A-4.89%Miss+13.6%N/AN/AMay 4, 2017$1.32B
    Dec 31, 2016$3.04$3.05N/A-0.33%Miss+7.4%N/AN/AFeb 9, 2017$1.23B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $44.38, down 2.8% from the year before. It was $11.56 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$44.38-2.8%
    Dec 31, 2024$45.64+4.2%
    Dec 31, 2023$43.78-2.6%
    Dec 31, 2022$44.96-39.9%
    Dec 31, 2021$74.78+136.3%
    Dec 31, 2020$31.65+28.4%
    Dec 31, 2019$24.64+7.9%
    Dec 31, 2018$22.83+40.0%
    Dec 31, 2017$16.31+41.1%
    Dec 31, 2016$11.56N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,52916
    2026Q2Jun 30, 20268,48117
    2026Q1Mar 31, 20268,03419
    2025Q4Dec 31, 20259,48016
    2025Q3Sep 30, 20259,16419
    2025Q2Jun 30, 20258,88019
    2025Q1Mar 31, 20257,86617
    2024Q4Dec 31, 20248,70318

    2026Q3 Earnings Call

    Opening remarks

    Ryan Crowe Senior Vice President, Investor Relations Thank you, Shannon. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our third quarter 2020 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes. Joining me on today's call are Dr. Leonard S. Schleifer, cofounder, board cochair, president and chief executive officer; Dr. George D. Yancopoulos, cofounder, board cochair, president, and chief scientific officer; Marion McCourt, executive vice president, commercial; and Christopher R. Fenimore, executive vice president, finance, and chief financial officer. For our call today, Len will briefly review key third quarter performance drivers and highlight a few emerging pipeline programs. George will then detail our recent pipeline progress, followed by Marion, who will review our commercial performance. Finally, Christopher will discuss our financial results and outlook. After our prepared remarks, the remaining time will be available for Q&A. I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement, changes to drug pricing regulations and requirements, and our drug pricing strategy, intellectual property, pending litigation, other proceedings, and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2026, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. In addition, please note that GAAP and non-GAAP financial measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of those measures to GAAP is available in our quarterly results press release and our corporate presentation, both of which can be found on the Regeneron Investor Relations website. Once our call concludes, the IR team will be available to answer any further questions. With that, let me turn the call over to our president and chief executive, Dr. Leonard S. Schleifer.

    Leonard S. Schleifer President and Chief Executive Officer Thank you, Ryan, and welcome to everyone joining our call today.

    Frequently Asked Questions About REGN

    When is Regeneron Pharmaceuticals's next earnings date?

    Regeneron Pharmaceuticals's next earnings report is expected for Jan 28, 2027.

    Did REGN beat earnings estimates last quarter?

    Yes. Regeneron Pharmaceuticals reported EPS of $18.43 for the quarter ended Sep 30, 2026, above the $13.76 estimate, a 33.94% surprise.

    What EPS do analysts expect from REGN next quarter?

    The consensus EPS estimate for Regeneron Pharmaceuticals for the quarter ending Dec 31, 2026 is $26.27 from 25 analysts, with estimates from $17.35 to $31.96.

    How often does REGN beat earnings estimates?

    Regeneron Pharmaceuticals beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +22.95%.